Company Profile
Avenue Therapeutics Stock Price, News & Analysis
- Ticker:
- ATXI
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Avenue Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
0.32 USD (+6.67%)
Close
Last updated: June 23, 2026 at 00:00
—
Market cap
Why the stock is moving
ATXI is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Avenue Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Avenue Therapeutics follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Avenue Therapeutics sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Source: Avenue Therapeutics
- 03
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
Source: Avenue Therapeutics
- 04
- 05
Avenue Therapeutics to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Source: Avenue Therapeutics
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Avenue Therapeutics (ATXI)?
Avenue Therapeutics (ATXI) most recently closed at 0.32 USD, a +6.67% move versus the previous session.
What does Avenue Therapeutics do?
Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is ATXI stock listed?
Avenue Therapeutics (ATXI) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Avenue Therapeutics is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Avenue?
Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Avenue Therapeutics targeting with Avenue?
Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Therapeutics?
Avenue Therapeutics is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.